Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain

K. Tanaka, N. Ogawa, Masato Asanuma, Y. Kondo, A. Mori

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The effects of chronic administration of ENA-713, an acetylcholinesterase (AChE) inhibitor, on pre- and postsynaptic cholinergic indices were examined in the senescent rat brain. In the senescent group, the acetylcholine (ACh) level was markedly reduced in the frontal cortex, hippocampus, striatum and thalamus + midbrain, but these reductions were completely prevented by ENA-713. Moreover, although choline acetyltransferase (ChAT) activity was also significantly decreased in these four regions, it recovered in the frontal cortex, hippocampus and thalamus + midbrain after ENA-713 treatment. In contrast, cholinesterase (ChE) activity was not changed in any experimental groups. The maximum number (Bmax) of muscarinic M1 receptor (M1-R) binding site in the frontal cortex in the senescent group was decreased without any change in affinity, but this decrease was also inhibited by ENA-713. Thus, these findings suggest that ENA-713 may have protective, neurotrophic and therapeutic effects on aging-induced cholinergic dysfunction and be useful for the treatment of aging-related dementia, such as the Alzheimer-type dementia.

Original languageEnglish
Pages (from-to)721-725
Number of pages5
JournalNeurobiology of Aging
Volume15
Issue number6
DOIs
Publication statusPublished - 1994

Fingerprint

Rivastigmine
Cholinesterase Inhibitors
Frontal Lobe
Brain
Mesencephalon
Thalamus
Cholinergic Agents
Hippocampus
Muscarinic M1 Receptors
Choline O-Acetyltransferase
Cholinesterases
Therapeutic Uses
Acetylcholine
Dementia
Alzheimer Disease
Binding Sites

Keywords

  • Acetylcholinesterase inhibitor
  • Cholinergic indices
  • Chronic administration
  • ENA-713
  • Fischer 344
  • Normal aging
  • Senescent rat brain

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain. / Tanaka, K.; Ogawa, N.; Asanuma, Masato; Kondo, Y.; Mori, A.

In: Neurobiology of Aging, Vol. 15, No. 6, 1994, p. 721-725.

Research output: Contribution to journalArticle

Tanaka, K. ; Ogawa, N. ; Asanuma, Masato ; Kondo, Y. ; Mori, A. / Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain. In: Neurobiology of Aging. 1994 ; Vol. 15, No. 6. pp. 721-725.
@article{694307c169ba48e1a4c02841a467767e,
title = "Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain",
abstract = "The effects of chronic administration of ENA-713, an acetylcholinesterase (AChE) inhibitor, on pre- and postsynaptic cholinergic indices were examined in the senescent rat brain. In the senescent group, the acetylcholine (ACh) level was markedly reduced in the frontal cortex, hippocampus, striatum and thalamus + midbrain, but these reductions were completely prevented by ENA-713. Moreover, although choline acetyltransferase (ChAT) activity was also significantly decreased in these four regions, it recovered in the frontal cortex, hippocampus and thalamus + midbrain after ENA-713 treatment. In contrast, cholinesterase (ChE) activity was not changed in any experimental groups. The maximum number (Bmax) of muscarinic M1 receptor (M1-R) binding site in the frontal cortex in the senescent group was decreased without any change in affinity, but this decrease was also inhibited by ENA-713. Thus, these findings suggest that ENA-713 may have protective, neurotrophic and therapeutic effects on aging-induced cholinergic dysfunction and be useful for the treatment of aging-related dementia, such as the Alzheimer-type dementia.",
keywords = "Acetylcholinesterase inhibitor, Cholinergic indices, Chronic administration, ENA-713, Fischer 344, Normal aging, Senescent rat brain",
author = "K. Tanaka and N. Ogawa and Masato Asanuma and Y. Kondo and A. Mori",
year = "1994",
doi = "10.1016/0197-4580(94)90054-X",
language = "English",
volume = "15",
pages = "721--725",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain

AU - Tanaka, K.

AU - Ogawa, N.

AU - Asanuma, Masato

AU - Kondo, Y.

AU - Mori, A.

PY - 1994

Y1 - 1994

N2 - The effects of chronic administration of ENA-713, an acetylcholinesterase (AChE) inhibitor, on pre- and postsynaptic cholinergic indices were examined in the senescent rat brain. In the senescent group, the acetylcholine (ACh) level was markedly reduced in the frontal cortex, hippocampus, striatum and thalamus + midbrain, but these reductions were completely prevented by ENA-713. Moreover, although choline acetyltransferase (ChAT) activity was also significantly decreased in these four regions, it recovered in the frontal cortex, hippocampus and thalamus + midbrain after ENA-713 treatment. In contrast, cholinesterase (ChE) activity was not changed in any experimental groups. The maximum number (Bmax) of muscarinic M1 receptor (M1-R) binding site in the frontal cortex in the senescent group was decreased without any change in affinity, but this decrease was also inhibited by ENA-713. Thus, these findings suggest that ENA-713 may have protective, neurotrophic and therapeutic effects on aging-induced cholinergic dysfunction and be useful for the treatment of aging-related dementia, such as the Alzheimer-type dementia.

AB - The effects of chronic administration of ENA-713, an acetylcholinesterase (AChE) inhibitor, on pre- and postsynaptic cholinergic indices were examined in the senescent rat brain. In the senescent group, the acetylcholine (ACh) level was markedly reduced in the frontal cortex, hippocampus, striatum and thalamus + midbrain, but these reductions were completely prevented by ENA-713. Moreover, although choline acetyltransferase (ChAT) activity was also significantly decreased in these four regions, it recovered in the frontal cortex, hippocampus and thalamus + midbrain after ENA-713 treatment. In contrast, cholinesterase (ChE) activity was not changed in any experimental groups. The maximum number (Bmax) of muscarinic M1 receptor (M1-R) binding site in the frontal cortex in the senescent group was decreased without any change in affinity, but this decrease was also inhibited by ENA-713. Thus, these findings suggest that ENA-713 may have protective, neurotrophic and therapeutic effects on aging-induced cholinergic dysfunction and be useful for the treatment of aging-related dementia, such as the Alzheimer-type dementia.

KW - Acetylcholinesterase inhibitor

KW - Cholinergic indices

KW - Chronic administration

KW - ENA-713

KW - Fischer 344

KW - Normal aging

KW - Senescent rat brain

UR - http://www.scopus.com/inward/record.url?scp=0028007356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028007356&partnerID=8YFLogxK

U2 - 10.1016/0197-4580(94)90054-X

DO - 10.1016/0197-4580(94)90054-X

M3 - Article

VL - 15

SP - 721

EP - 725

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 6

ER -